Dyax and MorphoSys Sign License Agreement on Antibody-Related Patents
News Nov 21, 2007
The agreement grants MorphoSys a fully paid-up license to a variety of phage display-related patents from Dyax as well as other patents, including several relating to methods for displaying and selecting antibodies and other proteins through the use of alternative types of display.
As part of the license agreement, MorphoSys gains the right to sublicense the patents in conjunction with its proprietary technology. The license agreement provides MorphoSys with flexibility for future technology development to further diversify its antibody technology portfolio and improve its offering for therapeutic, diagnostic and research customers. Financial terms were not disclosed.
Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, stated, “This agreement with MorphoSys recognizes the true value of our intellectual property portfolio as our powerful proprietary display technologies continue to be attractive to many companies in the biotechnology and pharmaceutical industry.”
Mr. Blair added, “We are pleased to have entered into this licensing agreement with MorphoSys.”
“We are very pleased about this agreement with Dyax, which provides us even greater flexibility for our future technology development plans,” commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019